摘要
Abstract
Objective:To evaluate the clinical efficacy and safety of different transcranial magnetic stimulation(TMS)protocols in the treatment of acute schizophrenia.Method:Using a random number table method,122 patients with acute schizophrenia admitted to Second People's Hospital of Baise from January 2022 to November 2023 were divided into the DL group and the DM group,with 61 patients in each.The DL group received TMS treatment targeting at the dorsolateral prefrontal cortex(DLPFC),while the DM group underwent TMS therapy targeting at the dorsomedial prefrontal cortex(DMPFC).Clinical efficacy,scores on the modified overt aggression scale(MOAS),the personal and social performance scale(PSP)and the MATRICS consensus cognitive battery(MCCB)were assessed before and after treatment in both groups,adverse reactions were recorded.Result:After treatment,the clinical efficacy of the DM group was slightly higher than that of the DL group,but the difference was not statistically significant(P>0.05).After treatment,the positive and negative symptom scale scores in the DL group were lower than those in the DM group(P<0.05);there was no statistically significant difference in the score of general psychopathology scale(P>0.05).After treatment,the MOAS and PSP scores in the DL group were lower than those in the DM group(P<0.05),and there was no statistically significant difference in MCCB score between the two groups(P>0.05).No severe adverse reactions were observed during the treatment in either group,and there was no significant difference in the incidence of adverse reactions between groups(P>0.05).Conclusion:TMS is a safe and effective treatment for acute schizophrenia.TMS at the DMPFC site is more advantageous in improving social and cognitive functions,while TMS at the DLPFC site is more beneficial in reducing overt aggressive behavior.关键词
经颅磁刺激/精神分裂症/安全性/认知功能Key words
Transcranial magnetic stimulation/Schizophrenia/Safety/Cognitive function
